Furthermore, a comparison of proteomic data of doxorubicin-treated fibroblasts and doxorubicin-treated ES cells identified a unique protein signature of 11 markers, among which COL6A2, PSME1 and FLNC demonstrated clinical significance by survival analysis GSE63155 for ES patients. This evidence concerns the gene PSME1 and Ewing sarcoma.